A DCE to Understand Patients' Preferences for Alternative Models of Care

Developing New Models of Care for People With Fibromyalgia: Designing a DCE to Understand Patients' Preferences for Alternative Models of Care

A pilot survey for a Discrete Choice Experience to understand the strength of patient's preferences for alternative models of care for fibromyalgia.

Study Overview

• Status: Completed
• Conditions: Fibromyalgia

Detailed Description

We will use the Discrete Choice Experiment (DCE) method to elicit preferences for alternative models of care for people with fibromyalgia. The DCE is a choice-based survey that quantifies preferences for attributes (or features) of goods, services or policy interventions. It assumes that any good or service (in this case models of care for fibromyalgia) can be described by its attributes and the measure (or 'levels') of these attributes. Each respondent faces a series of hypothetical scenarios (choice sets) composed of two or more alternatives. In each choice set, respondents are asked to choose their preferred scenario. The principle underlying a DCE is choices are made based on the features (or attributes) of different actions. Therefore, a DCE enables researchers to gain insight into the relative importance of each attribute, and the trade-offs between attributes.

This study is a survey of participants identified from a previous study about chronic widespread pain ("MAintaining MusculOskeleTal Health" - MAmMOTH). As part of the MAmMOTH study, a randomly selected sample of adults aged 25 years and over registered with participating general practices in Scotland were mailed a screening questionnaire. All individuals who returned the completed screening questionnaire and who met some criteria for fibromyalgia and consented to be contacted for future health survey research were approached for a further survey, the DEHLTA study. The DEHLTA survey questionnaire asked participants if they had ever received a diagnosis of fibromyalgia. From respondents to the DEHLTA study, individuals who said they had a diagnosis of fibromyalgia and who consented to be contacted for future studies will be eligible to participate in the current pilot study. We estimate this will be approximately 80 individuals.

Inclusion criteria are:

• Reporting a diagnosis of fibromyalgia in the DEHLTA survey
• Consenting to be contacted for future health survey research in the DEHLTA survey

Exclusion criteria are:

• Not reporting a diagnosis of fibromyalgia in the DEHLTA survey
• Not consenting to be contacted for future health survey research in the DEHLTA survey

Eligible individuals will receive a one-off paper questionnaire (including an invitation letter, a patient information sheet, and a prepaid, preaddressed envelope) and be invited to participate in the current study. A reminder letter will be mailed two weeks later. Mailings will be carried out by study staff at the University of Aberdeen.

We will analyse the feasibility of the model of data collection and quality of the questionnaire responses by estimating response rate, questionnaire completion times, item response and qualitative feedback on question items. In addition, we will assess frequencies and associations in choice responses to examine the strength of preferences relating to service provision in terms of the specified attributes (time to diagnosis, diagnosis provider, treatment type, waiting time, and type of on-going help and support). The data analysis conducted will inform the design of a larger study involving participants from a national patient organisation.

• Study Type: Observational
• Enrollment (Actual): 41

Contacts and Locations

Study Locations

• United Kingdom
  • Aberdeen, United Kingdom
    • University of Aberdeen

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Respondents to a previous survey questionnaire who had told us they had a diagnosis of fibromyalgia

Description

Inclusion Criteria:

• Reporting a diagnosis of fibromyalgia in the DEHLTA survey
• Consenting to be contacted for future health survey research in the DEHLTA survey

Exclusion Criteria:

• Not reporting a diagnosis of fibromyalgia in the DEHLTA survey
• Not consenting to be contacted for future health survey research in the DEHLTA survey

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Patient Preferences for treatment for fibromyalgia	This will be derived from the participants' answers to discrete choice questions	The outcome will be measured at a single timepoint, i.e. the time of completion of the survey questionnaire. The survey will be carried out during August and September 2021.

Collaborators and Investigators

• Sponsor: University of Aberdeen

Study record dates

Study Major Dates

• Study Start (Actual): August 25, 2021
• Primary Completion (Actual): October 8, 2021
• Study Completion (Actual): October 8, 2021

Study Registration Dates

• First Submitted: September 3, 2021
• First Submitted That Met QC Criteria: September 13, 2021
• First Posted (Actual): September 22, 2021

Study Record Updates

• Last Update Posted (Actual): May 23, 2022
• Last Update Submitted That Met QC Criteria: May 20, 2022
• Last Verified: May 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nervous System Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Muscular Diseases; Neuromuscular Diseases; Fibromyalgia; Myofascial Pain Syndromes
• Other Study ID Numbers: 2-041-21

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No